Citalopram as adjunctive therapy in bipolar depression

D. J. Kupfer, K. N R Chengappa, A. J. Gelenberg, R. M A Hirschfeld, J. F. Goldberg, G. S. Sachs, V. J. Grochocinski, P. R. Houck, A. B. Kolar

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Background: The treatment of bipolar depression remains a major clinical challenge. The effectiveness and safety of adjunctive citalopram were evaluated in DSM-IV - Diagnosed bipolar depressed patients in a 5-site study. Method: The treatment strategy consisted of an open-label add-on design in which patients received 8 weeks of acute treatment with citalopram adjunctive to their ongoing treatment with mood stabilizers. Ongoing treatment with 1 antipsychotic, 1 anxiolytic, and 1 hypnotic agent was permitted. Responders to the 8-week trial then received 16 weeks of additional treatment with citalopram. Results: Forty-five subjects entered the trial; 12 dropped out before the end of the acute treatment phase. Of the 33 patients who completed the acute treatment phase, 64% (N = 21) were responders and 36% (N = 12) were nonresponders. In the continuation phase of the study, 14 patients achieved sustained remission, 3 patients did not achieve remission before completing 16 weeks of continuation treatment, 2 patients experienced a relapse, and 2 patients dropped out of the study and did not have a chance to remit. In spite of the extensive concomitant medication usage allowed in this study, citalopram treatment was well tolerated and the level of reported adverse events (including headache, nausea, diarrhea, and sexual dysfunction) relatively low. Conclusion: The high response rate, the high rate of sustained remission, and the low rate of adverse events strongly support the use of citalopram as a treatment for bipolar I or II depression. These findings should stimulate a controlled double-blind trial to demonstrate even more clearly the usefulness of this drug in the therapeutic regimen for bipolar disorder.

Original languageEnglish (US)
Pages (from-to)985-990
Number of pages6
JournalJournal of Clinical Psychiatry
Volume62
Issue number12
StatePublished - 2001

Fingerprint

Citalopram
Bipolar Disorder
Therapeutics
Anti-Anxiety Agents
Hypnotics and Sedatives
Diagnostic and Statistical Manual of Mental Disorders
Nausea
Antipsychotic Agents
Headache
Diarrhea

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Kupfer, D. J., Chengappa, K. N. R., Gelenberg, A. J., Hirschfeld, R. M. A., Goldberg, J. F., Sachs, G. S., ... Kolar, A. B. (2001). Citalopram as adjunctive therapy in bipolar depression. Journal of Clinical Psychiatry, 62(12), 985-990.

Citalopram as adjunctive therapy in bipolar depression. / Kupfer, D. J.; Chengappa, K. N R; Gelenberg, A. J.; Hirschfeld, R. M A; Goldberg, J. F.; Sachs, G. S.; Grochocinski, V. J.; Houck, P. R.; Kolar, A. B.

In: Journal of Clinical Psychiatry, Vol. 62, No. 12, 2001, p. 985-990.

Research output: Contribution to journalArticle

Kupfer, DJ, Chengappa, KNR, Gelenberg, AJ, Hirschfeld, RMA, Goldberg, JF, Sachs, GS, Grochocinski, VJ, Houck, PR & Kolar, AB 2001, 'Citalopram as adjunctive therapy in bipolar depression', Journal of Clinical Psychiatry, vol. 62, no. 12, pp. 985-990.
Kupfer DJ, Chengappa KNR, Gelenberg AJ, Hirschfeld RMA, Goldberg JF, Sachs GS et al. Citalopram as adjunctive therapy in bipolar depression. Journal of Clinical Psychiatry. 2001;62(12):985-990.
Kupfer, D. J. ; Chengappa, K. N R ; Gelenberg, A. J. ; Hirschfeld, R. M A ; Goldberg, J. F. ; Sachs, G. S. ; Grochocinski, V. J. ; Houck, P. R. ; Kolar, A. B. / Citalopram as adjunctive therapy in bipolar depression. In: Journal of Clinical Psychiatry. 2001 ; Vol. 62, No. 12. pp. 985-990.
@article{595a3418482949eb9ab6afba36ca872a,
title = "Citalopram as adjunctive therapy in bipolar depression",
abstract = "Background: The treatment of bipolar depression remains a major clinical challenge. The effectiveness and safety of adjunctive citalopram were evaluated in DSM-IV - Diagnosed bipolar depressed patients in a 5-site study. Method: The treatment strategy consisted of an open-label add-on design in which patients received 8 weeks of acute treatment with citalopram adjunctive to their ongoing treatment with mood stabilizers. Ongoing treatment with 1 antipsychotic, 1 anxiolytic, and 1 hypnotic agent was permitted. Responders to the 8-week trial then received 16 weeks of additional treatment with citalopram. Results: Forty-five subjects entered the trial; 12 dropped out before the end of the acute treatment phase. Of the 33 patients who completed the acute treatment phase, 64{\%} (N = 21) were responders and 36{\%} (N = 12) were nonresponders. In the continuation phase of the study, 14 patients achieved sustained remission, 3 patients did not achieve remission before completing 16 weeks of continuation treatment, 2 patients experienced a relapse, and 2 patients dropped out of the study and did not have a chance to remit. In spite of the extensive concomitant medication usage allowed in this study, citalopram treatment was well tolerated and the level of reported adverse events (including headache, nausea, diarrhea, and sexual dysfunction) relatively low. Conclusion: The high response rate, the high rate of sustained remission, and the low rate of adverse events strongly support the use of citalopram as a treatment for bipolar I or II depression. These findings should stimulate a controlled double-blind trial to demonstrate even more clearly the usefulness of this drug in the therapeutic regimen for bipolar disorder.",
author = "Kupfer, {D. J.} and Chengappa, {K. N R} and Gelenberg, {A. J.} and Hirschfeld, {R. M A} and Goldberg, {J. F.} and Sachs, {G. S.} and Grochocinski, {V. J.} and Houck, {P. R.} and Kolar, {A. B.}",
year = "2001",
language = "English (US)",
volume = "62",
pages = "985--990",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "12",

}

TY - JOUR

T1 - Citalopram as adjunctive therapy in bipolar depression

AU - Kupfer, D. J.

AU - Chengappa, K. N R

AU - Gelenberg, A. J.

AU - Hirschfeld, R. M A

AU - Goldberg, J. F.

AU - Sachs, G. S.

AU - Grochocinski, V. J.

AU - Houck, P. R.

AU - Kolar, A. B.

PY - 2001

Y1 - 2001

N2 - Background: The treatment of bipolar depression remains a major clinical challenge. The effectiveness and safety of adjunctive citalopram were evaluated in DSM-IV - Diagnosed bipolar depressed patients in a 5-site study. Method: The treatment strategy consisted of an open-label add-on design in which patients received 8 weeks of acute treatment with citalopram adjunctive to their ongoing treatment with mood stabilizers. Ongoing treatment with 1 antipsychotic, 1 anxiolytic, and 1 hypnotic agent was permitted. Responders to the 8-week trial then received 16 weeks of additional treatment with citalopram. Results: Forty-five subjects entered the trial; 12 dropped out before the end of the acute treatment phase. Of the 33 patients who completed the acute treatment phase, 64% (N = 21) were responders and 36% (N = 12) were nonresponders. In the continuation phase of the study, 14 patients achieved sustained remission, 3 patients did not achieve remission before completing 16 weeks of continuation treatment, 2 patients experienced a relapse, and 2 patients dropped out of the study and did not have a chance to remit. In spite of the extensive concomitant medication usage allowed in this study, citalopram treatment was well tolerated and the level of reported adverse events (including headache, nausea, diarrhea, and sexual dysfunction) relatively low. Conclusion: The high response rate, the high rate of sustained remission, and the low rate of adverse events strongly support the use of citalopram as a treatment for bipolar I or II depression. These findings should stimulate a controlled double-blind trial to demonstrate even more clearly the usefulness of this drug in the therapeutic regimen for bipolar disorder.

AB - Background: The treatment of bipolar depression remains a major clinical challenge. The effectiveness and safety of adjunctive citalopram were evaluated in DSM-IV - Diagnosed bipolar depressed patients in a 5-site study. Method: The treatment strategy consisted of an open-label add-on design in which patients received 8 weeks of acute treatment with citalopram adjunctive to their ongoing treatment with mood stabilizers. Ongoing treatment with 1 antipsychotic, 1 anxiolytic, and 1 hypnotic agent was permitted. Responders to the 8-week trial then received 16 weeks of additional treatment with citalopram. Results: Forty-five subjects entered the trial; 12 dropped out before the end of the acute treatment phase. Of the 33 patients who completed the acute treatment phase, 64% (N = 21) were responders and 36% (N = 12) were nonresponders. In the continuation phase of the study, 14 patients achieved sustained remission, 3 patients did not achieve remission before completing 16 weeks of continuation treatment, 2 patients experienced a relapse, and 2 patients dropped out of the study and did not have a chance to remit. In spite of the extensive concomitant medication usage allowed in this study, citalopram treatment was well tolerated and the level of reported adverse events (including headache, nausea, diarrhea, and sexual dysfunction) relatively low. Conclusion: The high response rate, the high rate of sustained remission, and the low rate of adverse events strongly support the use of citalopram as a treatment for bipolar I or II depression. These findings should stimulate a controlled double-blind trial to demonstrate even more clearly the usefulness of this drug in the therapeutic regimen for bipolar disorder.

UR - http://www.scopus.com/inward/record.url?scp=0035661759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035661759&partnerID=8YFLogxK

M3 - Article

C2 - 11780881

AN - SCOPUS:0035661759

VL - 62

SP - 985

EP - 990

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 12

ER -